Degussa Fiscal 93/94 Profits Surge

16 January 1995

German company Degussa, which incorporates the Asta Medical Group, reports group pretax income up a massive 63% to 280 million Deutschemarks ($177.9 million) and earnings per share up from 12 marks to 22 marks for the fiscal year ended September 1994. Sales for the period improved 7% to 13.8 billion marks ($8.77 billion).

Sales in the pharmaceutical sector, which now account for 22% of group turnover (20% the previous year), rose 5% to 2.15 billion marks. Degussa notes that this is the first time there has been consolidation of the Dutch dental company Elephant BV, which contributed three percentage points to this growth.

Earnings improved notably, and it is said that the Asta Medical Group achieved a significantly higher level of profitability due to its timely implementation of restructuring and efficiency improvement programs. The dental division achieved good results, but slightly lower than those of the previous year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight